Skip to main content Skip to navigation
RB780 Mouse Anti-Human CD7
Product Details
Down Arrow Up Arrow


BD Horizon™
LEU-9; T-cell leukemia antigen; T-cell surface antigen Leu-9
Human (QC Testing)
Mouse BALB/c IgG2a, κ
T-acute lymphoblastic leukemia cells
Flow cytometry (Routinely Tested)
5 µl/test
II T 31; III T 563; V NK12; VI T 6T-R7, T 6T-CD7.2, BP 494, BP 543
924
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions and unreacted dye was removed.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

Product Notices

  1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  2. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
  3. Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
  4. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
  5. An isotype control should be used at the same concentration as the antibody of interest.
  6. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  7. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  9. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
  10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
569216 Rev. 2
Antibody Details
Down Arrow Up Arrow
4H9

The 4H9 (Leu-9) monoclonal antibody specifically recognizes human CD7 which is also known as T-cell leukemia antigen, T-cell surface antigen Leu-9, and  LEU-9. CD7 is a ~40 kDa type I transmembrane glycoprotein that has an extracellular region with an N-terminal IgV-like domain followed by an extended O-glycosylated stalk region, a transmembrane region and cytoplasmic tail. The CD7 antigen is expressed throughout T-lymphocyte differentiation. It is present on 85% to 90% of peripheral blood T lymphocytes. In normal individuals, CD7 is expressed on all CD8+ lymphocytes, approximately 90% of CD4+ lymphocytes, and most NK cells. CD7 is weakly expressed on monocytes but not on granulocytes or B lymphocytes. It is expressed on hematopoietic progenitors and 50% of thymocytes. In leukemias, the CD7 antigen is present on the majority of T-lymphoid lineages. CD7 may function in cellular adhesion and play a role in interactions between T cells as well as T cells and B cells.

569216 Rev. 2
Format Details
Down Arrow Up Arrow
RB780
The BD Horizon RealBlue™ 780 (RB780) Dye is part of the BD family of blue dyes. It is a tandem fluorochrome with an excitation maximum (Ex Max) at 498-nm and an emission maximum (Em Max) at 781-nm. Driven by BD innovation, RB780 can be used on both spectral and conventional cytometers and is designed to be excited by the Blue laser (488-nm) with minimal excitation by the 561-nm Yellow-Green laser. For conventional instruments equipped with a Blue laser (488-nm), RB780 can be used as an alternative to PE-Cy7 and we recommend using an optical filter centered near 780-nm (eg, a 780/60-nm bandpass filter). For spectral instruments equipped with a Blue laser (488-nm), it can be used in conjunction with PE-Cy7. RB780 is on average brighter than PE-Cy7 and has minimal spillover into Yellow-Green detectors.
altImg
RB780
Blue 488 nm
498 nm
781 nm
569216 Rev.2
Citations & References
Down Arrow Up Arrow
View product citations for antibody "569216" on CiteAb

Development References (9)

  1. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma.. Blood. 1986; 68(1):1-31. (Clone-specific). View Reference
  2. Link M, Warnke R, Finlay J, et al. A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies.. Blood. 1983; 62(4):722-8. (Immunogen: Flow cytometry). View Reference
  3. Palker TJ, Scearce RM, Hensley LL, Ho W, Haynes BF. Comparison of the CD7 (3A1) group of T cell workshop antibodies. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II. Human T Lymphocytes. New York, NY: Springer-Verlag; 1986:303-313.
  4. Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma.. Am J Pathol. 1987; 128(1):181-201. (Clone-specific: Immunohistochemistry). View Reference
  5. Rabinowich H, Pricop L, Herberman RB, Whiteside TL. Expression and function of CD7 molecule on human natural killer cells. J Immunol. 1994; 152(2):517-526. (Clone-specific: Flow cytometry). View Reference
  6. Weiss LM, Crabtree GS, Rouse RV, Warnke RA. Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas.. Am J Pathol. 1985; 118(2):316-24. (Clone-specific: Immunohistochemistry). View Reference
  7. Weiss LM, Wood GS, Warnke RA. Immunophenotypic differences between dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides.. Am J Pathol. 1985; 120(2):179-85. (Clone-specific: Immunohistochemistry). View Reference
  8. Wood GS, Abel EA, Hoppe RT, Warnke RA. Leu-8 and Leu-9 antigen phenotypes: immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation.. J Am Acad Dermatol. 1986; 14(6):1006-13. (Clone-specific: Immunohistochemistry). View Reference
  9. Zola H, Swart B, Nicholson I, Voss E. CD7. In: Zola H. Leukocyte and stromal cell molecules : the CD markers. Hoboken, N.J.: Wiley-Liss; 2007:52.
View All (9) View Less
569216 Rev. 2

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.